Is Coral Labs. overvalued or undervalued?

As of 3 October 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 10.09, an EV to EBITDA of 4.67, and a Price to Book Value of 0.93, which indicate a favorable valuation compared to its peers.
In comparison to its peers, Coral Labs has a lower PE ratio than Sun Pharma (34.04) and Divi's Lab (67.54), both of which are categorized as expensive. Additionally, the company's EV to EBITDA is significantly lower than that of its peers, suggesting it is trading at a discount relative to the industry. Despite a challenging year-to-date return of -31.57% compared to the Sensex's 3.93%, Coral Labs has shown strong performance over the longer term, with a 3-year return of 96.50%.